



# Dendritic Scaffold onto Titanium Implants. A Versatile Strategy Increasing Biocompatibility



Noemí Molina, Ana González, Donato Monopoli, Belinda Mentado, José Becerra, Leonor Santos-Ruiz, Ezequiel Pérez-Inestrosa and Yolanda Vida






**Figure S1.**  $^1\text{H}$  NMR spectrum of 3,3'-diazidopivalic acid (**2**) in  $\text{CDCl}_3$ .




**Figure S2.**  $^{13}\text{C}$  NMR (SEFT) spectrum of 3,3'-diazidopivalic acid (**2**) in  $\text{CDCl}_3$ .

**Figure S3.**  $^1\text{H}$  NMR spectrum of benzyl-3,3'-diazidopivaloate (**3**) in  $\text{CDCl}_3$ .**Figure S4.**  $^{13}\text{C}$  NMR (SEFT) spectrum of benzyl-3,3'-diazidopivaloate (**3**) in  $\text{CDCl}_3$ .


**Figure S5.** <sup>1</sup>H NMR spectrum of benzyl-3,3'-diaminopivaloate (**4**) in D<sub>2</sub>O.**Figure S6.** <sup>13</sup>C NMR (SEFT) spectrum of benzyl-3,3'-diaminopivaloate (**4**) in MeOD-*d*<sub>4</sub>




**Figure S7.**  $^1\text{H}$  NMR spectrum of benzyl-3,3'-bis(tert-butoxycarbonyl)aminopivaloate (**5**) in  $\text{CDCl}_3$ .





**Figure S8.**  $^{13}\text{C}$  NMR (SEFT) spectrum of benzyl-3,3'-bis(tert-butoxycarbonyl)aminopivaloate (**5**) in  $\text{CDCl}_3$ .




**Figure S9.** <sup>1</sup>H NMR spectrum of 3,3'-bis(tert-butoxycarbonyl)aminopivalic acid (**6**) in MeOH-d<sub>4</sub>.






**Figure S10.** <sup>13</sup>C NMR (SEFT) spectrum of 3,3'-bis(tert-butoxycarbonyl)aminopivalic acid (**6**) in DMSO-d<sub>6</sub>.

Figure S11.  $^1\text{H}$  NMR spectrum of 7 in  $\text{CDCl}_3$ .Figure S12.  $^{13}\text{C}$  NMR (SEFT) spectrum of 7 in  $\text{CDCl}_3$ .

**Figure S13.** HSQC spectrum of 7 in  $\text{CDCl}_3$ .**Table S1.** NMR signals assignments of compound 7.

Position	$^1\text{H}$ NMR (ppm)	$^{13}\text{C}$ NMR (ppm)
d,h	-	174.9
Bocco	-	157.2
Bnc	-	130.1
BnCH	7.40–7.29 (m, 5 H)	128.8, 128.6, 128.5
Bocc	-	79.6
BnCH <sub>2</sub>	5.15 (s, 2 H)	67.3
b,f	-	48.6
b,f	-	48.0
a,e	3.51–3.06 (m, 12 H)	44.8
a,e	3.51–3.06 (m, 12 H)	42.2
BocCH <sub>3</sub>	1.44 (s, 36 H)	28.5
c,g	1.17–1.05 (m, 9 H)	19.4



**Figure S16.** HSQC spectrum of **1** in MeOD-*d*<sub>4</sub>.**Table S2.** NMR signals assignments of compound **1**.

Position	<sup>1</sup> H NMR (ppm)	<sup>13</sup> C NMR (ppm)
d,h	-	177.5
Bocco	-	158.7
Bocc	-	80.3
b,f	-	49.8
b,f	-	46.0
a,e	3.48–3.20 (m, 12 H)	45.3
a,e	3.48–3.20 (m, 12 H)	43.7
BocCH <sub>3</sub>	1.44 (s, 36 H)	28.8
c,g	1.18–1.03 (m, 9 H)	20.3
c,g	1.18–1.03 (m, 9 H)	19.5